Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia

StatusSuspended
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Not Yet Recruiting → Suspended Sponsor's reason: PI requested Show 4 more changesShow less
    • Start date changed from estimate of Sep 27, 2026 to Apr 21, 2026
    • Eligibility criteria expanded, about 26 words
    • Study description expanded, about 6 words
    • Site contact updated
  2. 2 versions Re-verified since Apr 29, 2026, no change to tracked fieldsv6-v7
  3. Start date: Feb 27, 2026 to Sep 27, 2026v5
  4. 3 versions Re-verified since Sep 30, 2025, no change to tracked fieldsv2-v4
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
To find out if giving blinatumomab as injections under the skin can help to control MRD and keep the disease from coming back in participants with B-cell ALL.
Trial Details
NCT Number NCT07192237
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Amgen
Conditions
(from sponsor)		 Phase 2 Study, Blinatumomab, Acute Lymphoblastic Leukemia
Related terms Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov